Addeo A - Search Results

1

Frisone D, Friedlaender A, Malapelle U, Banna G, Addeo A. Frisone D, et al. Among authors: addeo a. Crit Rev Oncol Hematol. 2020 Aug;152:103008. doi: 10.1016/j.critrevonc.2020.103008. Epub 2020 May 26. Crit Rev Oncol Hematol. 2020. PMID: 32485528 Review.

2

Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario.

Addeo A, Tabbò F, Robinson T, Buffoni L, Novello S. Addeo A, et al. Crit Rev Oncol Hematol. 2018 Feb;122:150-156. doi: 10.1016/j.critrevonc.2017.12.015. Epub 2017 Dec 30. Crit Rev Oncol Hematol. 2018. PMID: 29458783 Free article. Review.

3

Adding an invasive procedure will not necessarily change treatment or outcome of NSCLC patients with preoperative clinical N1 disease.

Addeo A, Banna G. Addeo A, et al. Eur Respir J. 2018 Apr 4;51(4):1800084. doi: 10.1183/13993003.00084-2018. Print 2018 Apr. Eur Respir J. 2018. PMID: 29618603 Free article. No abstract available.

4

Oral Metronomic Vinorelbine in Advanced Non-small Cell Lung Cancer Patients Unfit for Chemotherapy.

Banna GL, Camerini A, Bronte G, Anile G, Addeo A, Rundo F, Zanghì G, Lal R, Libra M. Banna GL, et al. Among authors: addeo a. Anticancer Res. 2018 Jun;38(6):3689-3697. doi: 10.21873/anticanres.12647. Anticancer Res. 2018. PMID: 29848729 Clinical Trial.

5

Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients' selection.

Banna GL, Passiglia F, Colonese F, Canova S, Menis J, Addeo A, Russo A, Cortinovis DL. Banna GL, et al. Among authors: addeo a. Crit Rev Oncol Hematol. 2018 Sep;129:27-39. doi: 10.1016/j.critrevonc.2018.06.016. Epub 2018 Jun 23. Crit Rev Oncol Hematol. 2018. PMID: 30097235 Review.

6

The crucial role of predicting brain metastases development in non-small cell lung cancer patients.

Addeo A, Banna GL. Addeo A, et al. J Thorac Dis. 2018 Sep;10(Suppl 26):S3305-S3307. doi: 10.21037/jtd.2018.08.95. J Thorac Dis. 2018. PMID: 30370144 Free PMC article. No abstract available.

7

PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

Addeo A, Banna GL. Addeo A, et al. Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S283-S286. doi: 10.21037/tlcr.2018.07.10. Transl Lung Cancer Res. 2018. PMID: 30393623 Free PMC article. No abstract available.

8

PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?

Addeo A, Banna GL. Addeo A, et al. Transl Lung Cancer Res. 2018 Sep;7(Suppl 3):S287-S289. doi: 10.21037/tlcr.2018.07.09. Transl Lung Cancer Res. 2018. PMID: 30393624 Free PMC article. No abstract available.

9

Corrigendum to "Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario" [Crit. Rev. Oncol./Hematol. 122 (February) (2018) 150-156].

Addeo A, Tabbò F, Robinson T, Buffoni L, Novello S. Addeo A, et al. Crit Rev Oncol Hematol. 2019 Jul;139:158. doi: 10.1016/j.critrevonc.2018.06.018. Epub 2018 Nov 2. Crit Rev Oncol Hematol. 2019. PMID: 30396775 No abstract available.

10

Metronomic oral vinorelbine for the treatment of advanced non-small cell lung cancer: a multicenter international retrospective analysis.

Camerini A, Banna GL, Cinieri S, Pezzuto A, Mencoboni M, Rosetti F, Figueiredo A, Rizzo P, Ricci A, Langenhoven L, Santo A, Addeo A, Amoroso D, Barata F. Camerini A, et al. Among authors: addeo a. Clin Transl Oncol. 2019 Jun;21(6):790-795. doi: 10.1007/s12094-018-1989-y. Epub 2018 Nov 17. Clin Transl Oncol. 2019. PMID: 30448956

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

220 results

Search Page

Filters